

Drug Monograph

Drug/Drug **Airduo[®] (fluticasone propionate and salmeterol) powder**
 Class: **for inhalation/ Inhaled Steroids**
 Prepared for: MO HealthNet
 Prepared by: Conduent-Heritage

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Airduo[®] is available as a multidose, inhalation-driven, dry powder inhaler for oral inhalation that meters 55 mcg, 113 mcg, or 232 mcg of fluticasone propionate with 14 mcg of salmeterol per actuation.

Manufacturer: Teva Respiratory, LLC, Frazer, PA 19355

Indications: Airduo[®] Respiclick[®] is indicated for the treatment of asthma in patients aged 12 years and older.

Costs: \$285 per inhaler of Airduo[®]. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications Non Preferred

Prepared By: Luke Boehmer Pharm.D.
 Date: August 3, 2017